Charles Swanton

From Wikipedia, the free encyclopedia

Charles Swanton

FRS FMedSci FRCP
Charles Swanton Royal Society.jpg
Charles Swanton at the Royal Society admissions day in London, July 2018
Born
Robert Charles Swanton

1972 (age 48–49)[1]
Poole, Dorset, England, UK[1]
EducationSt Paul's School, London
Alma materUniversity College London (MD, PhD)
AwardsEllison–Cliffe Lecture (2017)
EMBO Member (2017)
Scientific career
FieldsCancer evolution[2]
InstitutionsFrancis Crick Institute
University College London
ThesisViral cyclin disruption of mammalian cell cycle control mechanisms (1998)
Doctoral advisorNic Jones
InfluencesJulian Downward
Websitewww.crick.ac.uk/research/a-z-researchers/researchers-p-s/charles-swanton/

(Robert) Charles Swanton FRS FMedSci FRCP is British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute,[3] Royal Society Napier Professor in Cancer[4] and thoracic medical oncologist at University College London[5] and University College London Hospitals,[6][7] co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.[8][9]

Education[]

Swanton completed was educated at St Paul's School, London[1] and completed his PhD in 1999[10] at what was then the Imperial Cancer Research Fund Laboratories (now the Francis Crick Institute) and his Cancer Research UK clinician scientist/medical oncology training in 2008.[7]

Research and career[]

Professor Swanton speaking at a conference in 2015

Swanton combines his laboratory research with clinical duties as co-director of the CRUK Lung Cancer Centre, focussed on how tumours evolve over space and time.[7] He has helped to define the branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome.[2][7][11][12]

Swanton is a co-founder of Achilles Therapeutics[13] with Sergio Quezada, Karl Peggs and Mark Lowdell. Achilles Therapeutics is a UCL/CRUK and Francis Crick Institute[14] biotechnology company funded by Syncona[15] that develops adoptive T cell therapies targeting clonal/truncal neo-antigens present in every tumour cell to limit drug resistance and tumour evolution.[citation needed]

Awards and honours[]

Personal life[]

Swanton is the son of Robert Howard Swanton (MD, FRCP) a consultant cardiologist at UCL.[23]

References[]

  1. ^ Jump up to: a b c Anon (2017). "Swanton, Prof. (Robert) Charles". Who's Who. ukwhoswho.com (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. doi:10.1093/ww/9780199540884.013.U286524. (subscription or UK public library membership required) (subscription required)
  2. ^ Jump up to: a b Charles Swanton publications indexed by Google Scholar Edit this at Wikidata
  3. ^ "Charles Swanton – The Francis Crick Institute". crick.ac.uk.
  4. ^ Anon (2016). "Leading scientists awarded Royal Society Research Professorships". royalsociety.org. Royal Society. Retrieved 27 November 2018.
  5. ^ https://web.archive.org/web/20170522065508/http://iris.ucl.ac.uk/iris/browse/profile?upi=CSWAN79
  6. ^ "The UCLH lung cancer service". uclh.nhs.uk. Retrieved 27 November 2018.
  7. ^ Jump up to: a b c d e f Anon (2018). "Professor Charles Swanton FMedSci FRS". London: Royal Society. One or more of the preceding sentences incorporates text from the royalsociety.org website where:

    "All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License." --"Archived copy". Archived from the original on 11 November 2016. Retrieved 27 June 2018.CS1 maint: archived copy as title (link) CS1 maint: bot: original URL status unknown (link)
  8. ^ https://www.cancerresearchuk.org/about-us/how-we-are-run/chief-executive-and-executive-board
  9. ^ Charles Swanton publications from Europe PubMed Central
  10. ^ Swanton, Robert Charles (1998). Viral cyclin disruption of mammalian cell cycle control mechanisms. london.ac.uk (PhD thesis). University College London (University of London). OCLC 941060556. EThOS uk.bl.ethos.286205.
  11. ^ Swanton, Charles; Mann, David J.; Fleckenstein, Bernhard; Neipel, Frank; Peters, Gordon; Jones, Nic (1997). "Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins". Nature. 390 (6656): 184–187. Bibcode:1997Natur.390..184S. doi:10.1038/36606. ISSN 0028-0836. PMID 9367157. S2CID 4397584.
  12. ^ Charles Swanton publications indexed by the Scopus bibliographic database. (subscription required)
  13. ^ "Our Team – Achilles Therapeutics". achillestx.com. Retrieved 27 November 2018.
  14. ^ UCL. "UCL spin-out Achilles Therapeutics to develop immunotherapies for cancer". UCL News. Retrieved 27 November 2018.
  15. ^ "Achilles Therapeutics". Syncona. Retrieved 27 November 2018.
  16. ^ "Pontecorvo Prize for best PhD thesis". cancerresearchuk.org. 28 October 2015. Retrieved 27 November 2018.
  17. ^ "Professor Charles Swanton – The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 27 November 2018.
  18. ^ Systems, eZ. "List of Award Winners / Fondazione San Salvatore". fondazionesansalvatore.ch. Archived from the original on 22 July 2018. Retrieved 27 November 2018.
  19. ^ "Translational Cancer Research Prize". cancerresearchuk.org. 28 October 2015. Retrieved 27 November 2018.
  20. ^ Jukic, Igor. "EMBO welcomes 65 new members". Embo.org. Retrieved 27 November 2018.
  21. ^ "Kraft Prize Symposium – Massachusetts General Hospital, Boston, MA". massgeneral.org. Retrieved 27 November 2018.
  22. ^ Azvolinsky, Anna (2018). "Cancer Evolutionist: A Profile of Charles Swanton". The Scientist.
  23. ^ Anon (2017). "Swanton, Robert Howard". Who's Who. ukwhoswho.com (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. doi:10.1093/ww/9780199540884.013.U4000216. (subscription or UK public library membership required) (subscription required)

 This article incorporates text available under the CC BY 4.0 license.

Retrieved from ""